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Abstract. Hepatocellular carcinoma (HCC) is the most common pri-
mary liver malignancy. Here, we performed high-resolution copy-
number analysis on 125 HCC tumors and whole-exome sequencing
on 24 of these tumors. We identiﬁed 135 homozygous deletions
and 994 somatic mutations of genes with predicted functional conse-
quences. We found new recurrent alterations in four genes (ARID1A,
RPS6KA3, NFE2L2 and IRF2) not previously described in HCC. Func-
tional analyses showed tumor suppressor properties for IRF2, whose
inactivation, exclusively found in hepatitis B virus (HBV)-related
tumors, led to impaired TP53 function. In contrast, inactivation of
chromatin remodelers was frequent and predominant in alcohol-
related tumors. Moreover, association of mutations in speciﬁc genes
(RPS6KA3-AXIN1 and NFE2L2-CTNNB1) suggested that Wnt/b-
catenin signaling might cooperate in liver carcinogenesis with both
oxidative stress metabolism and Ras/mitogen-activated protein
kinase (MAPK) pathways. This study provides insight into the
somatic mutational landscape in HCC and identiﬁes interactions
between mutations in oncogene and tumor suppressor gene muta-
tions related to speciﬁc risk factors.
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Abstract. Hepatocellular carcinoma (HCC) is the third leading cause
of cancer-related death worldwide. We sequenced and analyzed the
whole genomes of 27 HCCs, 25 of which were associated with hepa-
titis B or C virus infections, including two sets of multicentric tumors.
Although no common somatic mutations were identiﬁed in the mul-
ticentric tumor pairs, their whole-genome substitution patterns were
similar, suggesting that these tumors developed from independent
mutations, although their shared etiological backgrounds may have
strongly inﬂuenced their somatic mutation patterns. Statistical and
functional analyses yielded a list of recurrently mutated genes. Multi-
ple chromatin regulators, including ARID1A, ARID1B, ARID2, MLL and
MLL3, were mutated in 50% of the tumors. Hepatitis B virus genome
integration in the TERT locus was frequently observed in a high clonal
proportion. Our whole-genome sequencing analysis of HCCs identiﬁed
the inﬂuence of etiological background on somatic mutation patterns
and subsequent carcinogenesis, as well as recurrent mutations in
chromatin regulators in HCCs.
 2012 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.
Hepatocellular carcinoma (HCC) ranks among the most deadly
cancers worldwide and is characterized by phenotypic and
molecular heterogeneity. Besides surgical resection or liver trans-
plantation, chemotherapeutic or even targeted therapeutic
options are limited, with sorafenib currently being the only
approved systemic treatment. Thus, the need for a more detailed
understanding of underlying molecular changes resulting in liver
cancer is imperative for effective therapeutic targeting [1].
Triggered by the Human Genome Project, major progress was
achieved in unravelling the genetic basis of HCC. Following the
ﬁrst studies from the Thorgeirsson and other laboratories, it
became increasingly clear that gene expression proﬁles of tumors
are clearly linked to prognosis, suggesting a high therapeutic13 vol. 58 j 622–624
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potential for speciﬁc targeting of identiﬁed genetic changes [2].
However, since these ﬁrst studies were performed almost a dec-
ade ago, many genetic signatures have been proposed, but only
very few have been validated independently [3]. Thus, it became
apparent that the molecular pathogenesis of HCC mirrors the
observed phenotypic heterogeneity and that a more detailed
understanding of the complexity of genetic changes involved in
HCC development is needed in order to achieve efﬁcient thera-
peutic targeting.
Over the past several years the revolution in technological
progress promoted the availability of high throughput (‘‘next
generation’’, NGS) sequencing technologies. As a result, it is
now possible to sequence whole genomes within days. As for
many other diseases, great promise rests on the expectation that
these NGS technologies will provide a signiﬁcantly higher resolu-
tion of the genetic landscape of HCC as well. So far, the number of
studies utilizing NGS to investigate molecular alterations in HCC
is very limited [3]. In recent volumes of Nature Genetics, Guichard
et al. and Fujimoto et al. reported on the ﬁrst representative
cohorts of HCC patients in which tumor samples and surrounding
tissues were sequenced by NGS [4,5]. These data obtain valuable
insights into HCC biology in many ways: (1) for an analysis of the
mutational spectrum in HCC; (2) for a detailed genetics compar-
ison between cohorts of different ethnical or etiological back-
grounds, an issue that was previously repeatedly adressed with
respect to treatment response to sorafenib in comparison to the
SHARP [6] and Asia Paciﬁc trials [7]; (3) for a detailed compara-
tive analysis of the mutational spectrum with other cancers
thereby identifying both key driver genes as well as distinct
entity speciﬁc carcinogenic alterations; (4) for a detailed compar-
ison of molecular changes obtained by different high-throughput
analyses such as gene expression proﬁling and NGS on a genome
wide level; (5) for multi-level integrative analyses of transcrip-
tomic, genomic and epigenomic changes to further pinpoint crit-
ical molecular changes in hepatocarcinogenesis [8].
The landscape of molecular alterations in HCC observed in
both studies was relatively broad with various numbers of muta-
tions found in the investigated HCCs. Comparable to other tumor
entities, in the European cohort this number ranged from 5 to 121
mutations per tumor [4]. This high and heterogeneous number of
genetic variations in HCC was conﬁrmed in the Asian study [5].
Thus, in contrast to previous hypotheses on HCC genetics, a
rather complex interaction of multiple mutations in one tumor
ﬁnally resulting in HCC development must now be assumed.
These data are in accordance with other cancers, such as colon
or breast cancer, where an average 60–80 mutations per tumor
have been described [9]. One of the biggest challenges of the
upcoming decade will be the development of molecular and
bioinformatics strategies to distinguish true genetic driver
changes critical to HCC development from by-stander changes
that are not relevant to cancer biology, in order to ﬁlter for the
most promising druggable targets for HCC treatment.
An interesting aspect is the assessment of genetic data from
diverse backgrounds of ethnicity and etiology of the underlying
liver disease, leading to distinct carcinogenic mechanisms. Thus,
an integration of the coincidental results from the European
cohort with large numbers of alcoholic liver disease and the Asian
cohort with a large number of hepatitis B induced HCC may lead
to genetically robust insights into hepatocarcinogenesis [4,5].
Both groups reported a high number of mutations in p53 and
Wnt signaling genes. By number and signiﬁcance level, bothJournal of Hepatology 201pathways are clearly dominant among other genetic alterations.
However, these results are to a large extent in agreement with
previously published results from transcriptomic and proteomic
investigations. Thus, the here presented in-depth analyses
strengthen existing evidence from multiple biological layers that
p53 and Wnt/b-catenin signaling is among the most common
molecular changes involved in HCC development. b-Catenin is a
well known oncogene described in many types of cancer,
including liver cancer. Furthermore, disruption of this pathway
is supposed to occur frequently (around 30%) and early during
hepatocarcinogenesis and has been linked to prognosis.
Similarly, p53 mutations were commonly detected before.
However, the incidence of these mutations varied signiﬁcantly
between African or Asian (10–60%) and Western countries
(10–20%). This was mainly attributed to environmental factors
such as aﬂatoxin.
Another interesting result of both studies was the genetic
alteration of genes involved in chromatin remodeling [10], an
alteration predominatly found in alcohol-related tumors. Overall,
around 16–24% of HCCs showed genetic alterations in this path-
way, thereby suggesting a causative association with hepatocyte
transformation and highlighting recent evidence for the key role
of epigenetics in hepatocarcinogenesis [11].
Both studies extensively analyzed single nucleotide varia-
tions, in particular nucleotide transversions, and demonstrated
an over-representation of G>T transversions. This proﬁle of nucle-
otide transversion distiguishes HCC development from other
studies where in similar experiments a predominant C:G>T:A
transition was reported. Intriguingly, in the European study,
these G>T transversions were even more signiﬁcantly enriched
in the non-transcribed DNA strand, less efﬁciently repaired geno-
toxic injury [4]. Furthermore, these changes were signiﬁcantly
more frequent in HCCs that developed in non-cirrhotic livers as
well as in well-differentiated tumors, suggesting that exposure
to genotoxic agents could contribute to hepatocarcinogenesis as
a mechanism independent of liver cirrhosis. Although these data
were established on a small cohort and deﬁnitely require inde-
pendent validation, this aspect may shed light on ongoing discus-
sions of HCC development in non-cirrhotic livers [12]. This will be
of particular signiﬁcance given the increasing importance of
NASH-derived HCCs [12].
Linking this novel genetic information to the effectiveness of
systemic treatment strategies for HCC in particular, will be chal-
lenging, but may subsequently lead to major progress in the
development of more effective, stratiﬁed treatment options. In
other cancer entities, such as melanoma or colorectal cancer,
such genetics-based stratiﬁcation of treatment resulted in some
major breakthroughs for systemic treatment. For example, one
of the most commonly found mutation in melanoma, BRAFV600E,
leads to the activation of ERK and, subsequently, to an increase
in proliferation and survival advantage, and deﬁnes a subgroup
of patients sensitive to treatment with BRAF or MEK inhibitors.
[13,14]. Similarly, in colorectal cancer, activating mutations
within KRAS predict resistance to anti-EGFR monoclonal antibody
treatment [15], warranting genetic stratiﬁcation prior to treat-
ment. With respect to HCC, it became clear from both publica-
tions, that p53 and Wnt signaling pathway mutations (in
particular CTNNB1) are rarely coincidental but mostly exclusive
to HCC. Thus, increasing stratiﬁcation of HCCs using p53 or
CTNNB1 mutations as molecular classiﬁers and subsequent eval-
uation of speciﬁc treatment options in the respective subgroups3 vol. 58 j 622–624 623
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Fig. 1. Graphical summary of the most relevant ﬁndings and vision of the
discussed publications.
International Hepatologymay be valuable for the development of successful targeting
strategies.
In summary, the two recently published NGS analyses of HCC
offer valuable novel insights into the genetics of liver cancer on a
unprecedented resolution compared to previous genetics data
available. They further validated an important role for p53 and
Wnt/b-catenin signaling in populations of distinct ethnical and
etiological backgrounds. Finally, these data may be a major aid
for entering a novel era in treatment and development of more
stratiﬁed treatment algorithms for systemic therapies in HCC
(Fig. 1).624 Journal of Hepatology 201Conﬂict of interest
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